Yervoy market seen rising to $9.93 million by 2030
The Business Research Company says the Yervoy market is on track for steady growth through 2030, driven by rising cancer cases, broader immunotherapy use and more combination treatments. North America led the market in 2025, while melanoma incidence continues to support demand for ipilimumab-based therapy.
Why it matters: - Yervoy is tied to the broader shift toward immunotherapy in cancer care, where demand is rising with higher cancer prevalence and more advanced treatment regimens. - The market’s projected growth signals continued commercial and clinical relevance for ipilimumab-based therapies in oncology.
What happened: - The Business Research Company released a market analysis on Yervoy, a prescription cancer treatment containing ipilimumab. - The report estimates the Yervoy market will grow from $6.01 million in 2025 to $6.66 million in 2026. - The report projects the market will reach $9.93 million by 2030. - The analysis says North America held the largest share of the Yervoy market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report includes a free sample and the full market report.
The details: - The forecast implies a 10.8% CAGR for 2026. - The longer-term forecast implies a 10.5% CAGR through 2030. - Earlier growth was driven by regulatory approvals for melanoma and other solid tumors. - Adoption was also supported by the success of CTLA-4 inhibition, broader use in oncology centers, unmet need in advanced cancer treatment and improved patient survival outcomes. - Future growth is linked to a broader immunotherapy pipeline, more combination regimens, higher global cancer incidence, more oncology research spending and advances in immune profiling. - The report says key trends include wider use of immune checkpoint inhibitors, more combination immunotherapies, expanded use in advanced cancer care, more hospital-based immuno-oncology services and a focus on long-term survival. - Yervoy contains ipilimumab, a monoclonal antibody that helps the immune system attack cancer cells. - The drug blocks the CTLA-4 receptor on T-cells, which normally suppresses immune responses. - By inhibiting CTLA-4, Yervoy strengthens the immune attack against tumors. - Rising melanoma incidence is a major growth driver for the market. - The report links that rise to higher sun exposure, lifestyle changes, greater UV radiation from ozone depletion, better awareness and improved diagnostic methods. - In January 2024, the American Cancer Society projected about 100,640 new melanoma cases in the U.S. in 2024, including 59,170 in men and 41,470 in women. - The American Cancer Society also projected about 8,290 melanoma deaths in the U.S. in 2024, including 5,430 men and 2,860 women.
Between the lines: - The report points to a market that is being shaped less by one-off drug demand and more by broader oncology spending, combination therapy strategies and the expanding role of immunotherapy. - The melanoma figures help explain why a therapy that targets advanced disease can remain commercially important even in a mature oncology market. - The focus on hospital-based immuno-oncology services suggests treatment delivery is becoming part of the market story, not just drug sales.
What's next: - The Business Research Company says the market’s next phase will be shaped by continued immunotherapy development, wider combination use and ongoing investment in oncology research. - The report’s dashboard, market attractiveness scoring and future trend analysis are positioned as tools for tracking competitive shifts in the sector. - Contact information for the report is included in the release for readers seeking more detail.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
American Business Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.